IMARC Group, a leading market research company, has recently released a report titled “Hospital Infection Therapeutics Market Report by Drug Type (Anti-bacterial Drugs, Anti-fungal Drugs, Anti-viral Drugs, and Others), Indication (Blood Stream Infections, Urinary Tract Infections, Surgical Site Infections, Pneumonia, and Others), and Region 2024-2032”. The study provides a detailed analysis of the industry, including the global hospital infection therapeutics market trends, size, share and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
The global hospital infection therapeutics market size reached US$ 12.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 18.9 Billion by 2032, exhibiting a growth rate (CAGR) of 4.55% during 2024-2032.
Request to Get the Sample Report: https://www.imarcgroup.com/hospital-infection-therapeutics-market/requestsample
Factors Affecting the Growth of the Hospital Infection Therapeutics Industry:
- Growing Incidence of Hospital-Acquired Infections (HAIs):
The rising incidence of hospital-acquired infections (HAIs) is one of the major factors boosting the market growth. Moreover, the prolonged hospital stays, the increased use of invasive devices like catheters and ventilators, and the frequent administration of antibiotics that contribute to the prevalence of these infections are fueling the market growth. Additionally, the growing demand for effective therapeutic solutions, as these infections lead to severe health complications and increased mortality rates, is acting as a growth-inducing factor. Besides this, the increasing awareness among healthcare providers and patients about the risks associated with HAIs, prompting hospitals and clinics to adopt advanced infection control measures and therapeutic options, is enhancing the market growth.
- Rapid Technological Advancements in Diagnostic and Therapeutic Solutions:
The development of rapid and accurate diagnostic techniques, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), that enhance the ability to identify causative pathogens and their resistance profiles quickly is boosting the market growth. This enables timely and targeted treatment, reducing the spread and severity of infections. Additionally, the rising innovations in antimicrobial therapy, including the development of novel antibiotics and antifungals that are crucial in combating drug-resistant strains of pathogens, are fostering the market growth. Besides this, the increasing investment by biopharmaceutical companies in research and development (R&D) to introduce new classes of antimicrobials with improved efficacy and safety profiles is fostering the market growth.
- Increasing Government Initiatives and Funding:
The rising government initiatives and increased funding are driving the market growth. In line with this, the growing recognition of the significant impact of HAIs on public health and healthcare costs, prompting governments to implement stringent regulations and guidelines to prevent and manage these infections, is fueling the market growth. Additionally, the heightened government funding for research and development (R&D) in antimicrobial resistance (AMR), with substantial investments aimed at discovering new antibiotics and alternative therapies, is catalyzing the market growth. Moreover, the introduction of public health campaigns and educational initiatives to raise awareness about HAIs and the importance of infection prevention measures is stimulating the market growth.
Speak to An Analyst: https://www.imarcgroup.com/request?type=report&id=2393&flag=C
Hospital Infection Therapeutics Market Report Segmentation:
By Drug Type:
- Anti-bacterial Drugs
- Anti-fungal Drugs
- Anti-viral Drugs
- Others
Anti-bacterial drugs accounted for the largest market share due to their widespread use in treating a broad range of bacterial infections common in hospital settings.
By Indication:
- Blood Stream Infections
- Urinary Tract Infections
- Surgical Site Infections
- Pneumonia
- Others
Surgical site infections represented the largest segment as these infections frequently occur post-operatively and require immediate and effective therapeutic intervention.
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Europe’s dominance in the hospital infection therapeutics market is attributed to its advanced healthcare infrastructure, stringent infection control policies, and substantial government funding for antimicrobial research.
Global Hospital Infection Therapeutics Market Trends:
The increasing adoption of wearable devices equipped with biosensors that can continuously monitor patients' vital signs and detect early signs of infection, facilitating timely intervention is boosting the market growth. Moreover, the growing popularity of personalized medicine, driven by advances in genomics and proteomics, paving the way for tailored therapeutic strategies that consider individual patient profiles, including genetic susceptibility to infections and response to specific treatments, is fueling the market growth. Furthermore, the rise of bacteriophage therapy in treating multidrug-resistant bacterial infections, as it offers a targeted method to combat specific pathogens without disrupting the beneficial microbiota, is enhancing the market growth.
Top Companies Operated in Hospital Infection Therapeutics Industry:
- Allergan Plc (AbbVie Inc.)
- AstraZeneca Plc
- Bayer Aktiengesellschaft
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche AG (Roche Holding AG)
- Gilead Sciences Inc.
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co. Inc
- Pfizer Inc.
- Sanofi S.A.
Key Highlights of the Report:
- Market Performance (2018-2023)
- Market Outlook (2024-2032)
- Market Trends
- Market Drivers and Success Factors
- Impact of COVID-19
- Value Chain Analysis
- Comprehensive mapping of the competitive landscape
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-631-791-1145
